CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Hypodermoclysis for Opioid Toxicity: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Last updated: July 8, 2020
Project Number: RA1123-000
Product Line: Rapid Response
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of hypodermoclysis for the treatment of opioid toxicity?
  2. What is the cost-effectiveness of hypodermoclysis for the treatment of opioid toxicity?
  3. What are the evidence-based guidelines regarding hypodermoclysis for the treatment of opioid toxicity?

Key Message

No evidence was identified regarding the clinical effectiveness and cost-effectiveness of hypodermoclysis for the treatment of opioid toxicity. Additionally, no evidence-based guidelines were identified regarding hypodermoclysis for the treatment of opioid toxicity.